Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4222-x
Abstract: BackgroundData are sparse regarding the feasibility of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited… read more here.
Keywords: psma rlt; baseline psma; rechallenge; adverse events ... See more keywords
Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
Sign Up to like & getrecommendations! Published in 2022 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001611
Abstract: Objective [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) is a promising therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and offers a survival benefit particularly to patients with only lymph node metastases. We therefore sought to evaluate… read more here.
Keywords: prostate cancer; node metastases; therapy; psma ... See more keywords
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
Sign Up to like & getrecommendations! Published in 2022 at "EJNMMI Research"
DOI: 10.1186/s13550-022-00891-1
Abstract: Background The recent phase III VISION-trial confirms the treatment efficacy of radioligand therapy with [ 177 Lu]PSMA-617 (PSMA-RLT) in metastatic castration-resistant prostate cancer (mCRPC). In PSMA-RLT, the relatively low absorbed bone marrow dose allows for… read more here.
Keywords: bone marrow; psma rlt; marrow impairment; psma ... See more keywords